April 23rd 2021
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
April 15th 2021
The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.
April 13th 2021
After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.
April 9th 2021
Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.
April 3rd 2021
Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.
The Impact of Sickle Cell Disease Severity on HRQOL and Economic Outcomes
Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.
Many Options, Many Updates to NCCN Guidelines in Multiple Myeloma
Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.
Lenacapavir Against HIV Demonstrates Ongoing Potential
The safety and effectiveness of the long-acting agent is backed by data from trials of the drug among treatment-experienced individuals living with HIV-1 whose viral load is on the rise due to other regimens failing. Investigation continues among these patients, as well as treatment-naive patients.
Report Describes Case of Improved Outcome in MM With Personalized Medicine
Researchers describe the case of an older patient who underwent myeloma drug sensitivity testing as part of an effort to identify the therapies most likely to produce a response in this difficult-to-treat population.
Marrow Lymphocyte Patterns After ASCT May Have Prognostic Value in MM
Patients with multiple myeloma (MM) often relapse over time despite initially achieving a complete response without minimal residual disease following induction treatment, leaving questions about changes in the immune system and the prognosis of the disease.
Trial of Anti-BCMA ide-cel for RRMM Leads to Undetectable Disease in 33% of Patients
More than 2 years after treatment, some of the patients with relapsed/refractory multiple myeloma have yet to see a relapse. An FDA decision on the therapy is expected within a month.
FDA Clears Peptide-Drug Conjugate for RRMM
The peptide-drug conjugate rapidly delivers an alkylating payload into tumor cells.
Combination Treatment Maintains Quality of Life in Relapsed/Refractory MM
Health-related quality of life was maintained when treating relapsed/refractory multiple myeloma (RRMM) with daratumumab in combination with bortezomib and dexamethasone.
Sustained MRD Negativity Predictive of Long-term Outcomes in RRMM
Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), and daratumumab-based combinations show higher rates of sustained MRD negativity compared with the standard of care.
Carfilzomib Improves Renal Response Compared With Bortezomib in RRMM
Carfilzomib-dexamethasone improved renal overall and complete response in patients with relapsed or refractory multiple myeloma (RRMM) compared with a regimen of bortezomib-dexamethasone in a real-world study.
What We’re Reading: EUA for Lilly’s Combination Treatment; COVID-19 Billing Waivers; Convalescent Plasma Indication Updated
The FDA issues an emergency use authorization (EUA) for Eli Lilly’s coronavirus disease 2019 (COVID-19) treatment; insurance waivers for COVID-19–related costs are starting to expire; new data update convalescent plasma’s indication.
Socioeconomic Status May Determine Patient Survival From Multiple Myeloma
Patients’ socioeconomic status is a significant factor in predicting survival rates for multiple myeloma, according to a new study.
Preclinical Study of Gene Therapy Vector for SCD, Beta-Thalassemia Shows Promise
An engineered lentivirus was created to avoid some of the drawbacks associated with current gene therapy vectors for sickle cell disease (SCD) and beta-thalassemia.
Impact of the Phase 3 APOLLO Trial Recent Findings
Key opinion leaders provide an overview of the recent findings from the APOLLO phase 3 study, and consider whether the findings have impacted their treatment algorithm in regards to potential for earlier response.
ASH 2020 Data: DKd Versus DVd Implications
A discussion on the practical implication of the data from the ASH (American Society of Hematology) 2020 Annual Meeting regarding DKd versus DVd.
Dr Mark Wildgust: Daratumumab Critical to Improving Patient Response
Daratumumab represents an important addition to the armamentarium of care for improving patient outcomes, said Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.
Higher Mortality Seen Among HSCT Recipients Who Contract COVID-19
Recipients of hematopoietic stem-cell transplantation (HSCT) who develop coronavirus disease 2019 (COVID-19) may be predisposed to a greater mortality rate if they meet certain disease criteria.
ASH 2020: COVID-19 and Hematology
Anthony Fauci gave his insight on the coronavirus disease 2019 (COVID-19) for immunocompromised populations at ASH 2020, and leading organizations released fact sheets and recommendations.
Therapy Selection for Newly Diagnosed Multiple Myeloma
Experts in the management of multiple myeloma discuss treatment selection for newly diagnosed patients, with consideration of the ENDURANCE trial and its shortcomings.
Clinical Significance of DKd Dosing Flexibility
Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial.
High-Antibody Convalescent Plasma Associated With Lower Mortality Among Patients With COVID-19
A comparison of 3 levels of SARS-CoV-2 antibodies in convalescent plasma shows that the 30-day death rate was lowest in the group receiving high-titer plasma.
CANDOR Trial Overview and Regimen Complications
An overview of the data from the CANDOR trial presented at the ASH (American Society of Hematology) 2020 annual meeting and discussion on how to manage various complications from the trial regimen.
Upfront Daratumumab Impact on Relapse Treatment
Key opinion leaders consider how the approval of daratumumab in the upfront setting for patients with relapsed multiple myeloma has impacted treatment strategies.
Natural Killer Cells Could Play Key Role in Fight Against MM
Emerging research into natural killer cells has shown promise, but the findings are complicated by the heterogeneity of multiple myeloma (MM).
Risk Factors for Increased Mortality Among Patients With MM, COVID-19 Identified
Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).
Treating Biochemical Relapses in Multiple Myeloma
Expert physicians provide insight into their strategy for treating biochemical relapse in patients with multiple myeloma.
Importance of MRD Negativity in Changing Relapse Patterns
A discussion on the importance of MRD (minimum residual disease) negativity in changing relapse patterns for patients with multiple myeloma.
Dr Robert Massie: Untreated Pooled Plasma Enabled Unchecked Virus Transmission
Decades ago, companies refused to heat-treat their blood products, which resulted in pooled plasma, among others, enabling many viruses to be transmitted, noted Robert K. Massie Jr, PhD, MA, of the Society for Progress.
R/R Multiple Myeloma Rationale for Decreased Response
Key opinion leaders discuss why patients with multiple myeloma experience increasingly decreased response to therapy over time.
Metabolic Biomarkers Could Predict Prognosis, Treatment Outcomes in MM
New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.
2 Clarke Drive Cranbury, NJ 08512